Last reviewed · How we verify
TQB2930+ chemotherapy
TQB2930 is a chemotherapy drug that targets cancer cells.
TQB2930 is a chemotherapy drug that targets cancer cells. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | TQB2930+ chemotherapy |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TQB2930 works by interfering with the growth and spread of cancer cells, but the exact mechanism is not well understood.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Nausea
- Fatigue
- Hair loss
Key clinical trials
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer (PHASE3)
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |